The city of Newport Beach, California, currently has 4 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: NewportNativeMD, Inc., Newport Beach, California
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: NewportNativeMD, Inc, Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Progressive Pulmonary Fibrosis
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
03/19/2024
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis